← Search & browse all drugs
RESPIRATORY SYSTEM › OTHER RESPIRATORY SYSTEM PRODUCTS › OTHER RESPIRATORY SYSTEM PRODUCTS › Respiratory stimulants
etamivan
R07AB04
Forms & Strengths
- Oral tablets: 50 mg, 100 mg
- Intravenous/Intramuscular solution: 50 mg/mL, 100 mg/mL
Adult Dosing
- Oral: 50 to 100 mg up to 3 to 4 times daily
- Intravenous/Intramuscular: 50 to 100 mg administered slowly as needed for respiratory depression
Pediatric Dosing
- Safety and efficacy not established in pediatric patients; use generally not recommended
Indications
- Respiratory stimulant in acute or chronic respiratory depression
- Barbiturate overdose adjunct for respiratory stimulation (historical)
Mechanism of Action
- Central nervous system stimulant that acts primarily on the medullary respiratory centers
- Increases sensitivity of the respiratory center to carbon dioxide, thereby increasing depth and rate of ventilation
Contraindications
- Hypersensitivity to etamivan or structurally related compounds
- Severe epilepsy or history of convulsive disorders
- Severe hypertension
- Acute mechanical airway obstruction
Adverse Reactions
- Central nervous system: Anxiety, restlessness, tremors, hyperreflexia, generalized seizures at high doses
- Cardiovascular: Hypertension, tachycardia, cardiac arrhythmias
- Gastrointestinal: Nausea, vomiting
- Respiratory: Cough, sneezing, dyspnea
Drug Interactions
- Other CNS stimulants: May lead to additive central nervous system stimulation and increased risk of seizures
- Monoamine oxidase inhibitors (MAOIs): Potential for severe hypertensive reactions
- Anticonvulsants: Anticonvulsant efficacy may be antagonized by the central stimulant effects of etamivan
Curated Content: Needs Vetting Before Put to Clinical Use